Adam Gridley

Adam Gridley is an accomplished Executive Officer with more than 20 years of experience in various aspects of business, particularly in the biotechnology, medical device, and pharmaceutical sectors. He has worked across a spectrum of organizations from venture capital-backed startups to well-established entities, demonstrating expertise in strategic transactions, fundraising, public offerings, and revenue growth.

His professional journey has been marked by significant achievements, including overseeing transactions and exits exceeding $530 million, raising over $70 million in venture capital and royalties, and orchestrating public offerings totaling more than $200 million. Adam has been a pivotal part of executive leadership teams where he played a key role in developing strategies, expanding revenues, building top-tier leadership teams, and securing FDA approvals for several products.

Adam Gridley has a diverse skill set that encompasses functional leadership in areas such as market development, international sales distribution, M&A, R&D, regulatory and clinical affairs, manufacturing, logistics, legal affairs, quality operations, finance, and IT. His expertise spans various domains including organization transformation, R&D, strategic planning, business development, investor relations, crisis management, product development, regulatory approvals, financial analysis, and cost management.

He pursued his higher education at the University of Denver, earning a Bachelor's degree and an MBA from the Daniels College of Business. Throughout his career, Adam has held numerous prestigious positions including Chief Executive Officer at Allay Therapeutics, Executive Chairman at LifeSprout, CEO at Entera Bio Ltd., and various senior executive roles at companies like Merz North America, Histogenics Corporation, Merz Aesthetics, BioForm Medical, Inc., and Gliatech.

Adam Gridley's involvement with organizations such as the Alliance for Regenerative Medicine showcases his commitment to the industry and his active participation in various boards and leadership roles. His contributions have been instrumental in driving growth, managing operations, and leading strategic initiatives across a range of companies in the healthcare and biotech sectors.